GlassScriptPhysician profile
Kathryn Dempsey
NPI 1861713273
$48,475.28
in general payments reported to CMS, 2019-2025
26 companies · $5,354 in 2025
The $5,354 reported for 2025 was more than what 90% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,178 · 2020: $344 · 2021: $191 · 2022: $220 · 2023: $15K · 2024: $26K · 2025: $5,354.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $44K · Food and Beverage: $1,869 · Travel and Lodging: $1,157 · Education: $15.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $43,500.00 |
| Food and Beverage | $1,869.47 |
| Travel and Lodging | $1,157.40 |
| Education | $15.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $45,592.47 | 2019-2025 | Nemluvio, Dysport, Epsolay |
| Abbvie INC. | $647.22 | 2019-2025 | Botox, Skyrizi, Rinvoq |
| Sun Pharmaceutical Industries INC. | $382.65 | 2020-2025 | Ilumya, Blu-U, Winlevi |
| Hill Dermaceuticals, INC. | $284.34 | 2025 | Tolak |
| Janssen Biotech, INC. | $267.27 | 2019-2024 | Tremfya, Stelara, Simponi Aria |
| Novartis Pharmaceuticals Corporation | $256.19 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $164.29 | 2019 | |
| Genzyme Corporation | $135.47 | 2019-2022 | |
| Pfizer INC. | $124.80 | 2019-2023 | |
| Ucb, INC. | $82.16 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $72.00 | 2019 | |
| Allergan, INC. | $71.16 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $51.78 | 2019-2021 | |
| Incyte Corporation | $48.93 | 2021-2023 | Opzelura |
| Dermavant Sciences, INC. | $46.75 | 2022-2023 | Vtama |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $44.27 | 2023-2025 | Sotyktu |
| Lilly USA, LLC | $35.94 | 2019-2020 | |
| Arcutis Biotherapeutics, INC. | $25.89 | 2023 | |
| Merz North America, INC. | $23.22 | 2025 | |
| Mayne Pharma Commercial LLC | $20.85 | 2019 | |
| Leo Pharma INC. | $18.41 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.45 | 2023 | Spevigo |
| Dermira, INC. | $17.05 | 2019 | |
| Botanix Sb INC | $15.66 | 2025 | Sofdra |
| Almirall LLC | $15.56 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $13.50 | 2023 | Seglentis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathryn Dempsey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.